Skip to main content
. 2022 Jul 2;15(9):2057–2074. doi: 10.1111/cts.13349

TABLE 2.

Top targets and approximate number of active CAR‐T cell therapies for hematological malignancies and solid tumors a

Hematological malignancies
Target CD19 BCMA CD22 CD20 CD123 CD33 CD30 CD38 CS1 TAA b
Approx. number of active therapies 542 166 80 64 60 39 38 30 22 2
Solid tumors
Target HER2 MSLN EGFR GD2 GPC2/3 MUC1 PSMA NY‐ESO‐1 EBV TAA b
Approx. number of active therapies 59 53 50 49 39 34 28 5 4 5
a

Table was derived from figure 2 in Upadhaya et al. 10 If the actual number is not available in the figure, digitization is used to estimate the number.

b

Undisclosed tumor‐associate antigen.